IGM Biosciences 주식 주식분석 | 주식가격 | 뉴스 | IGMS | US4495851085 | A2PPQK

날짜	IGM Biosciences 주식 가격
	10.45 undefined
	10.81 undefined
	10.86 undefined
	9.94 undefined
	9.59 undefined
	9.15 undefined
	9.27 undefined
	8.72 undefined
	8.88 undefined
	8.83 undefined
	8.62 undefined
	9.06 undefined
	8.48 undefined
	9.26 undefined
	8.39 undefined
	8.75 undefined
	9.68 undefined
	11.16 undefined
	10.89 undefined
	11.37 undefined
	11.18 undefined

날짜	IGM Biosciences 매출	IGM Biosciences EBIT	IGM Biosciences 이익
2029e	555.47 백만 undefined	0 undefined	-99.33 백만 undefined
2028e	359.36 백만 undefined	-41.89 백만 undefined	-160.13 백만 undefined
2027e	224.36 백만 undefined	-133.76 백만 undefined	-161.34 백만 undefined
2026e	51.74 백만 undefined	-243.61 백만 undefined	-164.42 백만 undefined
2025e	10.63 백만 undefined	-241.03 백만 undefined	-190.59 백만 undefined
2024e	46.7 백만 undefined	-185.73 백만 undefined	-165.37 백만 undefined
2023	2.13 백만 undefined	-263.46 백만 undefined	-246.42 백만 undefined
2022	1.07 백만 undefined	-227.96 백만 undefined	-221.1 백만 undefined
2021	0 undefined	-165.32 백만 undefined	-165.16 백만 undefined
2020	0 undefined	-83.28 백만 undefined	-81.36 백만 undefined
2019	0 undefined	-44.5 백만 undefined	-43.13 백만 undefined
2018	0 undefined	-22.79 백만 undefined	-22.71 백만 undefined
2017	0 undefined	-11.15 백만 undefined	-11.05 백만 undefined

	매출	EBIT	이익
2017	0 USD	-11.15 백만 USD	-11.05 백만 USD
2018	0 USD	-22.79 백만 USD	-22.71 백만 USD
2019	0 USD	-44.5 백만 USD	-43.13 백만 USD
2020	0 USD	-83.28 백만 USD	-81.36 백만 USD
2021	0 USD	-165.32 백만 USD	-165.16 백만 USD
2022	1.07 백만 USD	-227.96 백만 USD	-221.1 백만 USD
2023	2.13 백만 USD	-263.46 백만 USD	-246.42 백만 USD
2024e	46.7 백만 USD	-185.73 백만 USD	-165.37 백만 USD
2025e	10.63 백만 USD	-241.03 백만 USD	-190.59 백만 USD
2026e	51.74 백만 USD	-243.61 백만 USD	-164.42 백만 USD
2027e	224.36 백만 USD	-133.76 백만 USD	-161.34 백만 USD
2028e	359.36 백만 USD	-41.89 백만 USD	-160.13 백만 USD
2029e	555.47 백만 USD	0 USD	-99.33 백만 USD

2017	2018	2019	2020	2021	2022	2023	2024e	2025e	2026e	2027e	2028e	2029e
0	0	0	0	0	1	2	46	10	51	224	359	555
-	-	-	-	-	-	100.00	2,200.00	-78.26	410.00	339.22	60.27	54.60
-	-	-	-	-	-	-	-	-	-	-	-	-
0	0	0	0	0	0	0	0	0	0	0	0	0
-11	-22	-44	-83	-165	-227	-263	-185	-241	-243	-133	-41	0
-	-	-	-	-	-22,700.00	-13,150.00	-402.17	-2,410.00	-476.47	-59.38	-11.42	-
-11	-22	-43	-81	-165	-221	-246	-165	-190	-164	-161	-160	-99
-	100.00	95.45	88.37	103.70	33.94	11.31	-32.93	15.15	-13.68	-1.83	-0.62	-38.13
28.89	28.89	30.49	30.75	33.48	41.54	52.31	0	0	0	0	0	0
-	-	-	-	-	-	-	-	-	-	-	-	-

2017	2018	2019	2020	2021	2022	2023

0.4	1.9	224.6	366.3	229.5	427.2	337.68
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.2	0.5	6.4	7	11.2	11.3	9.92
0.6	2.4	231	373.3	240.7	438.5	347.6
0.7	1.5	18	34.8	56.3	73.1	74.01
0	0	12	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.1	0.1	0.3	0.5	1	2	1.81
0.8	1.6	30.3	35.3	57.3	75.1	75.81
1.4	4	261.3	408.6	298	513.6	423.41

40.8	60.9	0.3	0.3	0.3	0.4	0.59
0.04	0	0.35	0.57	0.6	0.86	1.02
-41.4	-64.1	-107.2	-188.6	-353.7	-574.8	-821.24
-34.6	-2.5	0	0	0	0	0
0	0	0	0	-100	-700	151
0.3	-4.9	240.2	381.7	244.9	287.3	203.23
0.2	0.2	3.1	7.9	5.6	2.5	1.33
0.5	3.6	5.8	9.3	22.2	39.4	37.38
0.2	0.1	0	0	0	2.7	3.78
0	5	0	0	0	0	0
0	0	0	0	0	0	0
0.9	8.9	8.9	17.2	27.8	44.6	42.48
0	0	0	0	0	0	0
0	0	0	0	0	0	0
0.1	0	12.2	9.6	25.4	181.6	177.7
0.1	0	12.2	9.6	25.4	181.6	177.7
1	8.9	21.1	26.8	53.2	226.2	220.18
1.3	4	261.3	408.5	298.1	513.5	423.41

2017	2018	2019	2020	2021	2022	2023
-11	-22	-43	-81	-165	-221	-246
0	0	0	1	4	6	8
0	0	0	0	0	0	0
0	2	-5	2	6	155	-6
0	0	3	18	55	98	99
0	0	0	0	0	0	0
0	0	0	0	0	0	0
-10	-20	-45	-67	-124	-5	-192
0	0	-2	-17	-13	-10	-12
0	0	-203	58	15	-225	68
0	0	-200	75	28	-215	80
0	0	0	0	0	0	0
0	5	15	0	0	0	0
8	17	269	215	3	218	113
8	22	282	214	2	219	115
0	0	-2,000	-1,000	0	0	1,000
0	0	0	0	0	0	0
-2	1	33	205	-107	-12	-8
-10.75	-20.83	-47.46	-85.38	-138.22	-16.06	-204.61
0	0	0	0	0	0	0

IGM Biosciences 브루토마진	IGM Biosciences EBIT-마진	IGM Biosciences 이익 마진
2029e	0 %	-17.88 %
2028e	-11.66 %	-44.56 %
2027e	-59.62 %	-71.91 %
2026e	-470.86 %	-317.8 %
2025e	-2,266.59 %	-1,792.31 %
2024e	-397.7 %	-354.1 %
2023	-12,369.06 %	-11,568.83 %
2022	-21,304.67 %	-20,663.55 %
2021	0 %	0 %
2020	0 %	0 %
2019	0 %	0 %
2018	0 %	0 %
2017	0 %	0 %

	EBIT-마진	이익 마진
2017	0 %	0 %
2018	0 %	0 %
2019	0 %	0 %
2020	0 %	0 %
2021	0 %	0 %
2022	-21,304.67 %	-20,663.55 %
2023	-12,369.06 %	-11,568.83 %
2024e	-397.7 %	-354.1 %
2025e	-2,266.59 %	-1,792.31 %
2026e	-470.86 %	-317.8 %
2027e	-59.62 %	-71.91 %
2028e	-11.66 %	-44.56 %
2029e	0 %	-17.88 %

날짜	IGM Biosciences 주당 매출	IGM Biosciences EBIT 당 주식	IGM Biosciences 주당 이익
2029e	9.41 undefined	0 undefined	-1.68 undefined
2028e	6.09 undefined	0 undefined	-2.71 undefined
2027e	3.8 undefined	0 undefined	-2.73 undefined
2026e	0.88 undefined	0 undefined	-2.79 undefined
2025e	0.18 undefined	0 undefined	-3.23 undefined
2024e	0.79 undefined	0 undefined	-2.8 undefined
2023	0.04 undefined	-5.04 undefined	-4.71 undefined
2022	0.03 undefined	-5.49 undefined	-5.32 undefined
2021	0 undefined	-4.94 undefined	-4.93 undefined
2020	0 undefined	-2.71 undefined	-2.65 undefined
2019	0 undefined	-1.46 undefined	-1.41 undefined
2018	0 undefined	-0.79 undefined	-0.79 undefined
2017	0 undefined	-0.39 undefined	-0.38 undefined

	주당 매출	EBIT 당 주식	주당 이익
2017	0 USD	-0.39 USD	-0.38 USD
2018	0 USD	-0.79 USD	-0.79 USD
2019	0 USD	-1.46 USD	-1.41 USD
2020	0 USD	-2.71 USD	-2.65 USD
2021	0 USD	-4.94 USD	-4.93 USD
2022	0.03 USD	-5.49 USD	-5.32 USD
2023	0.04 USD	-5.04 USD	-4.71 USD
2024e	0.79 USD	0 USD	-2.8 USD
2025e	0.18 USD	0 USD	-3.23 USD
2026e	0.88 USD	0 USD	-2.79 USD
2027e	3.8 USD	0 USD	-2.73 USD
2028e	6.09 USD	0 USD	-2.71 USD
2029e	9.41 USD	0 USD	-1.68 USD

	주식 수량
2017	28.89 백만 Aktien
2018	28.89 백만 Aktien
2019	30.49 백만 Aktien
2020	30.75 백만 Aktien
2021	33.48 백만 Aktien
2022	41.54 백만 Aktien
2023	52.31 백만 Aktien
2024e	52.31 백만 Aktien
2025e	52.31 백만 Aktien
2026e	52.31 백만 Aktien
2027e	52.31 백만 Aktien
2028e	52.31 백만 Aktien
2029e	52.31 백만 Aktien

EPS-예상치	EPS-실제	보고 분기
-0.85	-0.83 (2.12 %)	2024 Q1
-1.05	-1.01 (4.11 %)	2023 Q4
-1.24	-1.04 (15.95 %)	2023 Q3
-1.46	-1.43 (2.24 %)	2023 Q2
-1.39	-1.33 (4.39 %)	2023 Q1
-1.27	-1.19 (6.4 %)	2022 Q4
-1.45	-1.32 (9.27 %)	2022 Q3
-0.96	-1.33 (-38.72 %)	2022 Q2
-1.65	-1.53 (7.05 %)	2022 Q1
-1.57	-1.5 (4.65 %)	2021 Q4
-1.39	-1.32 (5.31 %)	2021 Q3
-1.19	-1.16 (2.56 %)	2021 Q2
-1	-0.95 (4.97 %)	2021 Q1
-0.89	-0.79 (10.83 %)	2020 Q4
-0.7	-0.66 (6.22 %)	2020 Q3
-0.66	-0.62 (5.76 %)	2020 Q2
-0.56	-0.58 (-3.39 %)	2020 Q1
-0.44	-0.49 (-11.06 %)	2019 Q4
-0.83	-2.41 (-189.32 %)	2019 Q3

%-지분	이름	주식	변경
6.93 %	Baker Bros. Advisors LP	4,090,316	399,305
5.77 %	T. Rowe Price Associates, Inc.	3,403,714	281,834
5.25 %	Invus Public Equities Advisors, LLC	3,100,422	578,178
5.02 %	Redmile Group, LLC	2,960,812	-10,730
2.88 %	Fidelity Management & Research Company LLC	1,698,506	-438,466
17.62 %	Haldor Topsoe Holding A/S	10,400,564	0
1.74 %	Goldman Sachs & Company, Inc.	1,029,043	591,942
1.59 %	RA Capital Management, LP	937,500	0
1.52 %	The Vanguard Group, Inc.	897,149	-1,549
1.18 %	BlackRock Institutional Trust Company, N.A.	694,047	-75,056
0.76 %	Schwarzer Fred M	449,452	152,386
0.68 %	Adage Capital Management, L.P.	400,000	400,000
0.55 %	Geode Capital Management, L.L.C.	326,656	34,124
0.52 %	State Street Global Advisors (US)	307,468	18,371
0.49 %	Behrens (M Kathleen)	287,859	3,078
0.42 %	Millennium Management LLC	247,196	-520,867
0.36 %	Citadel Advisors LLC	211,508	192,656
0.34 %	Rhenman & Partners Asset Management AB	200,000	0
0.31 %	Keyt (Bruce)	185,013	66,324
0.26 %	Samsara BioCapital, LLC	154,664	0
0.23 %	T. Rowe Price International Ltd	138,142	9,852
0.23 %	Exome Asset Management LLC	135,596	135,596
0.21 %	Hudson Bay Capital Management LP	124,260	0
0.20 %	Charles Schwab Investment Management, Inc.	120,817	21,052
0.20 %	Northern Trust Investments, Inc.	118,804	1,269
0.15 %	Tahir (Misbah)	90,418	40,810
0.14 %	Topsoe (Jakob Haldor)	84,854	1,734
0.14 %	TD Asset Management Inc.	83,452	0
0.14 %	Takimoto (Chris H.)	82,513	40,826
0.13 %	T. Rowe Price Investment Management, Inc.	78,388	0
0.13 %	Woodline Partners LP	75,000	0
0.12 %	Loberg (Michael D)	68,296	1,138
0.11 %	Bruce & Company, Inc.	65,000	-55,000
0.11 %	Pennant Investors, LP	64,900	64,900
0.09 %	Topsoe (Christina Teng)	53,406	2,687
0.08 %	Nuveen LLC	49,099	-30,088
0.08 %	Manulife Investment Management (North America) Limited	48,942	0
0.08 %	PGIM Quantitative Solutions LLC	47,470	47,470
0.08 %	D. E. Shaw & Co., L.P.	47,245	-28,669
0.08 %	Eagle Bay Family Office	44,635	0
0.07 %	Morgan Stanley & Co. LLC	43,201	28,581
0.07 %	Decker (Lisa Lynn)	41,389	25,374
0.07 %	Morgan Stanley Smith Barney LLC	39,687	-12,415
0.07 %	Gauthier (George A.)	39,642	560
0.07 %	Dimensional Fund Advisors, L.P.	39,453	-720
0.06 %	Oigaard (Emil)	37,375	37,375
0.06 %	Renaissance Technologies LLC	36,600	-54,300
0.06 %	BNY Mellon Asset Management	36,464	-3,058
0.06 %	BlackRock Investment Management, LLC	35,758	94
0.06 %	Jane Street Capital, L.L.C.	35,635	35,635
0.05 %	AllianceBernstein L.P.	32,300	-3,060
0.05 %	BlackRock Financial Management, Inc.	32,274	-4,912
0.05 %	PanAgora Asset Management Inc.	30,273	30,273
0.05 %	Susquehanna Portfolio Strategies, LLC	30,209	30,209
0.05 %	State of Wisconsin Investment Board	29,600	17,872
0.05 %	Prelude Capital Management, LLC	29,421	-7,800
0.05 %	Exchange Traded Concepts, LLC	27,935	8,887
0.04 %	Weber (Steven)	26,507	17,757
0.04 %	BofA Global Research (US)	24,732	9,252
0.04 %	Barclays Bank PLC	24,490	17,313
0.03 %	Rhumbline Advisers Ltd. Partnership	19,204	508
0.03 %	PGIM Fixed Income	18,400	18,400
0.03 %	Northern Trust Global Investments	17,992	1,632
0.03 %	Avantis Investors	17,107	10,768
0.02 %	Virtus Etf Advisers LLC	14,243	4,334
0.02 %	Susquehanna International Group, LLP	13,656	13,656
0.02 %	UBS Financial Services, Inc.	13,200	6,199
0.02 %	Parametric Portfolio Associates LLC	12,056	5,263
0.02 %	Brevan Howard Capital Management LP	11,877	11,877
0.02 %	DWS Investments UK Limited	11,702	11,702
0.02 %	Pale Fire Capital SE	11,601	-1,000
0.02 %	Goldman Sachs Asset Management, L.P.	11,466	-8,426
0.02 %	Gesiuris Asset Management S.G.I.I.C., S.A.	9,970	1,970
0.02 %	JPMorgan Private Bank (United States)	9,540	9,540
0.02 %	Amundi Asset Management, SAS	9,196	0
0.02 %	Mellon Investments Corporation	9,171	0
0.02 %	Dimensional Fund Advisors, Ltd.	9,055	0
0.01 %	Acadian Asset Management LLC	8,367	8,367
0.01 %	DNB Asset Management AS	8,043	-291
0.01 %	Abaris Investment Management AG	8,000	3,000
0.01 %	Principal Global Investors (Equity)	6,780	-684
0.01 %	SunAmerica Asset Management, LLC	6,604	650
0.01 %	New York State Common Retirement Fund	6,494	-33
0.01 %	State Street Global Advisors Ireland Limited	6,384	-23
0.01 %	BNY Mellon Wealth Management	6,362	2,987
0.01 %	Vaughan Nelson Investment Management, L.P.	5,057	0
0.01 %	Mirae Asset Global Investments (USA) LLC	4,241	0
0.01 %	Wells Fargo Bank, N.A.	4,110	1,134
0.01 %	NISA Investment Advisors, L.L.C.	3,900	3,847
0.01 %	Voya Investment Management LLC	3,313	-1,301
0.01 %	Invesco Capital Management LLC	3,250	3,250
0.01 %	Lee (Michael Stewart)	3,168	492
0.00 %	RBC Wealth Management, International	2,834	831
0.00 %	ProShare Advisors LLC	2,388	442
0.00 %	RBC Capital Partners	2,370	2,370
0.00 %	California State Teachers Retirement System	2,187	-11,995
0.00 %	Hambleton Julie	2,000	0
0.00 %	Citi Investment Research (US)	1,887	1,450
0.00 %	Simplex Trading, LLC	1,810	1,810
0.00 %	Horizon Kinetics LLC	1,793	0

이름	관계	이주간 상관관계	원월 상관관계	삼개월 상관계수	여섯달 상관관계	일년간 상관관계	이년 상관관계
AbCellera Biolog	공급업체고객	0,94	0,96	0,46	0,85	0,87	-
BeiGene	공급업체고객	0,51	0,84	0,05	0,90	0,78	0,50
Atreca A	공급업체고객	-0,12	0,82	0,13	0,70	0,93	0,66
Avid Bioservices	공급업체고객	-0,16	0,74	-0,09	0,82	0,44	-0,09
Medivir B	공급업체고객	-0,73	0,35	-0,18	0,86	0,36	0,03

What values and corporate philosophy does IGM Biosciences represent?

IGM Biosciences Inc represents values of innovation, integrity, and dedication in the field of biotechnology. With a strong emphasis on developing transformative and personalized therapies, IGM Biosciences Inc aims to improve the lives of patients suffering from serious diseases. The company's corporate philosophy revolves around scientific excellence, collaboration with experts, and a patient-centric approach. By leveraging its proprietary antibody engineering technology, IGM Biosciences Inc strives to create novel therapeutics that address significant unmet medical needs. Their commitment to advancing scientific research and delivering effective treatments underscores their mission to make a positive impact on global healthcare.

In which countries and regions is IGM Biosciences primarily present?

IGM Biosciences Inc is primarily present in the United States.

What significant milestones has the company IGM Biosciences achieved?

IGM Biosciences Inc has achieved several significant milestones. Notably, the company successfully completed its initial public offering in March 2020, raising approximately $175 million. Furthermore, IGM Biosciences has made substantial progress in advancing its pipeline of IgM antibody-based therapeutics. They have initiated clinical trials for their lead product candidate, IGM-2323, designed to treat patients with solid and hematologic malignancies. Additionally, the company has established strategic partnerships with renowned academic institutions and biopharmaceutical companies to further their research and development efforts. These achievements highlight IGM Biosciences' commitment to developing innovative therapies and advancing the field of immunoglobulin M (IgM) antibodies.

What is the history and background of the company IGM Biosciences?

IGM Biosciences Inc is a renowned biotechnology company based in Mountain View, California. Established in 2010, the company focuses on the development of innovative immunotherapies for the treatment of cancer and other diseases. With a strong emphasis on research and development, IGM Biosciences Inc utilizes its proprietary platform technology, called IgM antibody technology, to develop next-generation antibodies for targeted therapy. The company has successfully collaborated with various pharmaceutical and biotech companies to advance its therapeutic pipeline. IGM Biosciences Inc aims to revolutionize the field of immunotherapy with its cutting-edge scientific approach and commitment to improving patient outcomes.

Who are the main competitors of IGM Biosciences in the market?

The main competitors of IGM Biosciences Inc in the market include established biotechnology companies such as Amgen, Inc., Gilead Sciences, Inc., and Genentech. These companies have a strong presence in the biopharmaceutical industry and compete with IGM Biosciences in terms of developing novel antibody therapies, conducting clinical trials, and commercializing their products. By continually innovating and leveraging its unique antibody engineering platform, IGM Biosciences strives to differentiate itself from its competitors and address unmet medical needs.

In which industries is IGM Biosciences primarily active?

IGM Biosciences Inc is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of IGM Biosciences?

IGM Biosciences Inc is a biotechnology company that focuses on the development and discovery of engineered IgM antibodies for the treatment of various diseases. With its innovative business model, IGM Biosciences Inc aims to leverage its expertise in antibody engineering to bring novel treatments to patients. The company utilizes its proprietary IgM antibody technology platform to create next-generation therapeutics with enhanced therapeutic potential. IGM Biosciences Inc is committed to addressing unmet medical needs and advancing the field of antibody-based therapies through its research and development efforts.

IGM Biosciences 2024의 P/E 비율은 얼마입니까?

IGM Biosciences의 P/E 비율은 -3.31입니다.

IGM Biosciences 2024의 KUV는 얼마입니까?

IGM Biosciences의 P/S 비율은 11.71입니다.

IGM Biosciences의 AlleAktien 품질 점수는 얼마인가요?

IGM Biosciences에 대한 AlleAktien 품질 점수는 3/10입니다.

IGM Biosciences 2024의 매출은 얼마인가요?

예상되는 IGM Biosciences 매출은 46.7 백만 USD입니다.

IGM Biosciences 2024의 이익은 얼마인가요?

예상되는 IGM Biosciences 이익은 -165.37 백만 USD입니다.

IGM Biosciences은 무엇을 하나요?

IGM Biosciences Inc. is a biotechnology company that develops innovative products for cancer immunotherapy. Its business model is based on researching, developing, and commercializing monoclonal antibodies targeted specifically at cancer cells. IGM Biosciences Inc. has developed an advanced antibody engineering process known as the Antibody Engineering Platform (ADAPTIR). This technology allows the company to develop antibodies that target cells more specifically and have a higher efficacy than conventional antibodies. IGM Biosciences Inc. works closely with its customers to develop customized antibodies tailored to their specific needs. The company also has its own product pipeline focused on developing antibodies for the treatment of various types of cancer. One of the key areas of IGM Biosciences Inc. is preclinical research and development. The company has an experienced team of scientists and researchers working on developing new antibodies and therapies. The company also invests significant resources in clinical research to ensure the safety and efficacy of its products. IGM Biosciences Inc. also offers a wide range of services, including antibody manufacturing, product formulation and testing, and bulk antibody delivery. The company works with a variety of customers, including pharmaceutical companies, biotechnology companies, and research institutions. Some of the products developed by IGM Biosciences Inc. include IGM-2323, an antibody targeted at CD20, a protein found on B cells. IGM-2323 has been developed for the treatment of non-Hodgkin lymphomas and other B-cell disorders. Another important product of IGM Biosciences Inc. is IGM-8444, an antibody that targets the death receptor 5 or DR5. DR5 is a protein that is overexpressed in many cancer cells, including those resistant to standard treatments. IGM-8444 has shown promising results in preclinical studies and could become an important component of cancer therapy in the future. IGM Biosciences Inc. is a company dedicated to developing customized antibodies to fight cancer. The company has a unique technology platform that allows it to develop highly specific and powerful antibodies. IGM Biosciences Inc. has an experienced team of scientists and researchers working on developing new antibodies and therapies to provide more effective treatment for cancer patients.

IGM Biosciences 배당금은 얼마입니까?

IGM Biosciences은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

IGM Biosciences이 얼마나 자주 배당을 지급하나요?

IGM Biosciences의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

IGM Biosciences ISIN이 무엇입니까?

IGM Biosciences의 ISIN은 US4495851085입니다.

IGM Biosciences WKN은 무엇인가요?

IGM Biosciences의 WKN은 A2PPQK입니다.

IGM Biosciences 티커는 무엇인가요?

IGM Biosciences의 티커는 IGMS입니다.

IGM Biosciences이 얼마만큼의 배당금을 지급합니까?

지난 12개월 동안 IGM Biosciences은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 IGM Biosciences은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

IGM Biosciences의 배당 수익률은 얼마입니까?

IGM Biosciences의 현재 배당 수익률은 입니다.

IGM Biosciences의 배당금은 언제 지급되나요?

IGM Biosciences은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

IGM Biosciences의 배당금은 얼마나 안전한가요?

IGM Biosciences은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

IGM Biosciences의 배당금은 얼마입니까?

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

IGM Biosciences이(가) 속해 있는 섹터는 어디인가요?

IGM Biosciences은 '건강' 섹터에 속합니다.

Wann musste ich die Aktien von IGM Biosciences kaufen, um die vorherige Dividende zu erhalten?

IGM Biosciences의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

IGM Biosciences의 마지막 배당금 지급일은 언제였습니까?

마지막 배당금 지급일은 입니다.

IGM Biosciences의 2023년도 배당금은 얼마였습니까?

2023년에 IGM Biosciences는 0 USD를 배당금으로 지급했습니다.

IGM Biosciences는 어떤 화폐로 배당금을 지급하나요?

IGM Biosciences의 배당금은 USD에 지급됩니다.

Scope 1 - 직접 방출	—
스코프 2 - 구매한 에너지로부터의 간접적인 배출	—
Scope 3 - 가치 창출 체인 내의 간접 배출	—
총 CO₂ 배출량	—
CO₂ 감소 전략	✅
석탄 에너지	❌
원자력	❌
동물 실험	✅
펠츠 & 레더	—
살충제	—
팜 오일	—
담배	❌
유전자 변형 생물체	❌
기후 개념	—
지속 가능한 임업	—
재활용 규정	❌
환경 친화적인 포장	❌
위험물질	❌
연료 소비량과 효율성	❌
물 사용량 및 효율성	❌

여성 직원 비율	—
관리 직위에서의 여성 비율	—
아시아 직원 비율	—
아시아 경영진 비율	—
히스패닉/라티노 직원 비율	—
히스패닉/라티노 관리 부문 지분	—
흑인 직원 비율	—
블랙 매니지먼트 지분	—
흰색 종업원의 비율	—
화이트 매니지먼트 지분	—
성인 콘텐츠	❌
알코올	❌
무기	—
총기	❌
도박	❌
군사 계약	❌
인권 개념	❌
개인정보 보호 정책	—
작업 및 건강 보호	✅
카톨릭	✅

환경 보고	❌
이해관계자 참여	❌
콜백 정책	❌
카르텔법	❌

증권거래소	IGM Biosciences 티커
프랑크푸르트	1K0.F
뮌헨	1K0.MU
NASDAQ	IGMS

IGM Biosciences 티커	IGM Biosciences FIGI
IGMS:US	BBG00PNR1BT2
IGMS:UA	BBG00Q26HJH8
IGMS:UC	BBG00Q26HJJ6
IGMS:UN	BBG00Q26HJL3
IGMS:UP	BBG00Q26HJM2
IGMS:UB	BBG00Q26HJP9
IGMS:UM	BBG00Q26HJR7
IGMS:UX	BBG00Q26HJS6
IGMS:UD	BBG00Q26HJY9
IGMS:UW	BBG00Q26HK03
IGMS:UF	BBG00Q26HK12
IGMS:VY	BBG00Q26HK21
IGMS:VJ	BBG00Q26HK30
IGMS:VK	BBG00Q26HK49
IGMS:VF	BBG00Q26HK58
1K0:GR	BBG00Q69CN57
1K0:GF	BBG00Q69CN66
1K0:GS	BBG00Q69CN93
1K0:GM	BBG00Q69CNB0
1K0:GZ	BBG00Q9K4W67
IGMSEUR:XS	BBG00Q9M5W53
IGMSEUR:XH	BBG00Q9M5W80
IGMSEUR:XF	BBG00Q9M5WB6
IGMSEUR:XE	BBG00Q9M5WD4
IGMSEUR:XJ	BBG00Q9M5WF2
IGMSEUR:XL	BBG00Q9M5WG1
IGMSEUR:XG	BBG00Q9M5WH0
IGMSEUR:XO	BBG00Q9M5WJ8
IGMSEUR:XA	BBG00Q9M5WN3
IGMSEUR:XT	BBG00Q9M5WQ0
IGMSEUR:XW	BBG00Q9M5WR9
IGMSEUR:XU	BBG00Q9M5WS8
IGMSEUR:XV	BBG00Q9M5WV4
IGMSEUR:XM	BBG00Q9M5WW3
IGMSEUR:EU	BBG00Q9M5X24
IGMSUSD:EP	BBG00S5HWQR3
IGMSUSD:EZ	BBG00S5HWQT1
IGMSUSD:XS	BBG00S5HWQV8
IGMSUSD:X2	BBG00S5HWQW7
IGMSUSD:XH	BBG00S5HWQY5
IGMSUSD:XF	BBG00S5HWR00
IGMSUSD:XE	BBG00S5HWR28
IGMSUSD:XJ	BBG00S5HWR37
IGMSUSD:XL	BBG00S5HWR46
IGMSUSD:XG	BBG00S5HWR55
IGMSUSD:XO	BBG00S5HWR64
IGMSUSD:XA	BBG00S5HWRB8
IGMSUSD:E1	BBG00S5HWRC7
IGMSUSD:XT	BBG00S5HWRD6
IGMSUSD:XW	BBG00S5HWRF4
IGMSUSD:XU	BBG00S5HWRG3
IGMSUSD:XV	BBG00S5HWRJ0
IGMSUSD:XM	BBG00S5HWRK8
IGMSUSD:XQ	BBG00S5HWRL7
IGMSUSD:XX	BBG00S5HWRM6
IGMSUSD:XZ	BBG00S5HWRN5
IGMSUSD:X1	BBG00S5HWRQ2
IGMSUSD:EU	BBG00S5HWRS0
IGMS:VG	BBG00X1PHTR9
IGMS:VP	BBG00X1SY747
IGMSGBP:XS	BBG011623X81
IGMSGBP:X2	BBG011623X90
IGMSGBP:XH	BBG011623XC6
IGMSGBP:XF	BBG011623XF3
IGMSGBP:XE	BBG011623XH1
IGMSGBP:XJ	BBG011623XJ9
IGMSGBP:XL	BBG011623XK7
IGMSGBP:XG	BBG011623XL6
IGMSGBP:XO	BBG011623XM5
IGMSGBP:XA	BBG011623XR0
IGMSGBP:E1	BBG011623XS9
IGMSGBP:XT	BBG011623XT8
IGMSGBP:XW	BBG011623XV5
IGMSGBP:XU	BBG011623XW4
IGMSGBP:XV	BBG011623XY2
IGMSGBP:XM	BBG011623XZ1
IGMSGBP:XQ	BBG011623Y07
IGMSGBP:XX	BBG011623Y16
IGMSGBP:XZ	BBG011623Y25
IGMSGBP:X1	BBG011623Y43
IGMSGBP:EU	BBG011623YD3
1K0:LA	BBG018H9SDK2
1K0:LU	BBG018J3FY94

한 눈에 저평가된 주식을 인식하세요 fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

가격

가격

티커IGMS

ISINUS4495851085

WKNA2PPQK

IGM Biosciences 주식 가격

가격

개요

인트라데이 기능

총 수익률 및 상대 가격 변동

해석 및 투자

IGM Biosciences 주가 이력

IGM Biosciences 주식 매출, EBIT, 이익 US4495851085 · A2PPQK

매출, 이익 & EBIT

매출, EBIT, 소득 이해하기

연간 분석 및 비교

투자 기대치 활용

투자 통찰력

IGM Biosciences 매출, 이익 및 EBIT 역사

IGM Biosciences 주식 지표

손익계산서

매출 성장

총 이익률

EBIT와 EBIT 마진

수입과 성장

발행 주식

연간 비교의 해석

기대치와 예측

재무 상태표

재무 상태표 이해

자산

부채

자본

년대비 분석

데이터 해석

IGM Biosciences 주식 마진 US4495851085 · A2PPQK

마진

매출 총이익률 이해

EBIT 마진 분석

매출 마진에 대한 인사이트

기대치 해석

비교 분석

IGM Biosciences 마진 역사

IGM Biosciences 주식 매출, EBIT, 주당 순이익 US4495851085 · A2PPQK

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

IGM Biosciences 매출, 이익 및 EBIT 주당 역사

IGM Biosciences 주식 및 주식 분석

IGM Biosciences Fair Value에 따른 평가

Fair Value

Fair Value 이해하기

수익 기반 Fair Value

매출 기반 Fair Value

배당 기반 Fair Value

기대치와 예측

비교 분석

IGM Biosciences 역사적인 P/E, EBIT 및 P/S에 따른 평가

IGM Biosciences 주식 수량 US4495851085 · A2PPQK

매출, EBIT 및 주당 이익

주당 매출

주당 EBIT

주당 수익

예상 값

IGM Biosciences 수익 예상

IGM Biosciences 수익 놀라움

Eulerpool ESG Scorecard© IGM Biosciences 주식을 위해

Eulerpool World ESG Rating (EESG©)

54/ 100

🌱 Environment

👫 Social

🏛️ Governance

환경

소셜 (사회적)

지배구조 (기업 경영)

IGM Biosciences 주식 주주 구조

IGM Biosciences 임원진 및 경영진

한 눈에 저평가된 주식을 인식하세요
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

티커
IGMS

ISIN
US4495851085

WKN
A2PPQK